Russell Alan J
Known title: Chief Scientific OfficerCIK: 0001853529
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,031 | $0 | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,238 | $141K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,273 | $99K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 390 | $17K | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 130,352 | $59K | 7/1/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 69,648 | $13K | 7/1/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 130,352 | $5.1M | 7/1/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 69,648 | $2.7M | 7/1/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 100,000 | $18K | 11/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 100,000 | $2.1M | 11/12/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 100,000 | $18K | 8/26/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 100,000 | $1.5M | 8/26/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,907 | $26K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,551 | $26K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,209 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 200 | $36 | 3/7/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 200 | $6K | 3/7/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 1,200 | $216 | 2/6/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,200 | $36K | 2/6/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 8,015 | $1K | 2/5/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,015 | $241K | 2/5/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 100,000 | $18K | 12/30/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 100,000 | $2.7M | 12/30/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 75,000 | $14K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 74,185 | $2.1M | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 815 | $24K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,576 | $30K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 172,585 | $1.6M | 12/26/2023 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,602 | $14K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 147,585 | $27K | 11/30/2021 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 25,000 | $11K | 11/30/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 441 | $8K | 11/15/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 38 | $745 | 11/15/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,562 | $167K | 11/12/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 15,595 | $309K | 11/11/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,681 | $75K | 11/11/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 11,746 | $231K | 11/10/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 580 | $12K | 11/10/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 16,864 | $336K | 11/9/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 12,712 | $258K | 11/9/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 9,017 | $182K | 11/8/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 6 | $124 | 11/5/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 13,036 | $256K | 11/5/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,392 | $146K | 11/4/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 20,822 | $374K | 11/3/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,243 | $80K | 11/3/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,119 | $22K | 11/3/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 17,519 | $305K | 11/2/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 469 | $8K | 11/1/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,307 | $24K | 10/15/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 126 | $2K | 10/15/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,749 | $105K | 10/14/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,270 | $23K | 10/11/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,902 | $107K | 10/8/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 13,018 | $242K | 10/7/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,108 | $38K | 10/6/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,404 | $99K | 10/5/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 100 | $2K | 10/4/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 274 | $5K | 10/1/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 11,226 | $189K | 9/29/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 618 | $11K | 9/29/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 14,610 | $253K | 9/28/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 11,594 | $208K | 9/27/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 17 | $314 | 9/27/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 20,100 | $365K | 9/24/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 21,763 | $399K | 9/23/2021 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,072 | $98K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.